



## King's Research Portal

DOI:

[10.1016/j.optha.2016.11.018](https://doi.org/10.1016/j.optha.2016.11.018)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Nag, A., Lu, H., Arno, M., Iglesias, A. I., Bonnemaier, P., Broer, L., Uitterlinden, A. G., Klaver, C. C. W., van Duijn, C., Hysi, P. G., & Hammond, C. J. (2016). Evaluation of the Myocilin Mutation Gln368Stop Demonstrates Reduced Penetrance for Glaucoma in European Populations. *Ophthalmology*.  
<https://doi.org/10.1016/j.optha.2016.11.018>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

**Evaluation of the myocilin mutation Gln368Stop (rs74315329)  
demonstrates reduced penetrance in European populations**

Abhishek Nag<sup>1</sup>, Han Lu<sup>2</sup>, Matthew Arno<sup>2</sup>, Adriana I. Iglesias<sup>3,4</sup>, Pieter  
Bonnemaier<sup>3,4</sup>, Linda Broer<sup>5</sup>, Andre G. Uitterlinden<sup>3,5,6</sup>, Caroline C.W.  
Klaver<sup>4</sup>, Cornelia van Duijn<sup>3</sup>, Pirro G. Hysi<sup>1,7</sup>, Christopher J. Hammond<sup>1,7</sup>

<sup>1</sup>Department of Twin Research and Genetic Epidemiology, King's College London, St. Thomas' Hospital,  
London, UK

<sup>2</sup>King's Genomics Facilities, King's College London, London, UK

<sup>3</sup>Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands

<sup>4</sup>Department of Ophthalmology, Erasmus Medical Center, Rotterdam, the Netherlands

<sup>5</sup>Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands

<sup>6</sup>Netherlands Consortium for Healthy Ageing, Netherlands Genomic Initiative, the Hague, the Netherlands

<sup>7</sup>Department of Ophthalmology, King's College London, London, UK

**Corresponding author**

Prof. Christopher J. Hammond

Department of Twin Research and Genetic Epidemiology,

King's College London,

St. Thomas' Hospital,

London

United Kingdom

Email: [chris.hammond@kcl.ac.uk](mailto:chris.hammond@kcl.ac.uk)

## **Financial Support**

The study was part-funded by Fight for Sight (A.N., P.G.H) and the International Glaucoma Association (C.J.H.). TwinsUK is supported by the Wellcome Trust (grant WT081878MA) and the European Commission's Seventh Framework Programme (FP7/2007–2013). SNP Genotyping was performed by National Eye Institute via NIH/CIDR (grant R01EY018246-01-1, PI Young TL) and the Wellcome Trust Sanger Institute. The study also receives support from the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London.

The sponsor or funding organization had no role in the design or the conduct of this research.

## **Conflict of Interest**

No conflicting relationship exists for any author

## **Running Title**

Gln368Stop myocilin mutation and glaucoma

## **Abbreviations and Acronyms**

MYOC (myocilin), POAG (primary open-angle glaucoma), OPTN (optineurin), GWAS (genome-wide association study), JOAG (juvenile open-angle glaucoma), OR (odds ratio), IOP (intraocular pressure), ORA

(Ocular Response Analyser), RS (Rotterdam Study), HRC (Haplotype  
Reference Consortium), GVFL (glaucomatous visual field loss), MAF  
(minor allele frequency), CI (confidence intervals), OMIM (Online  
Mendelian Inheritance in Man)

57

58

59

60

61

62

63

64

65

66

67

68

69

70

## Abstract

**OBJECTIVE:** Sequence variations in the myocilin (*MYOC*) gene account for ~2–4% of the glaucoma cases. One particular *MYOC* mutation, Gln368Stop (dbSNP accession number: rs74315329), is the most common genetic mutation causing glaucoma, by raising the intraocular pressure. The objective of this study was to evaluate the effect of this *MYOC* mutation on intraocular pressure using data from large-scale European population panels (directly sequenced and imputation-based).

**DESIGN:** Cross-sectional, cohort study

**PARTICIPANTS:** For this study (combined sample size of over 17,000), the discovery and the replication phases were conducted in population-based cohorts, the TwinsUK and the Rotterdam Study, respectively.

**METHODS:** Carriers of the risk allele for rs74315329 were identified using whole-genome sequencing and imputation data (based on 1000 Genomes and Haplotype Reference Consortium panels). The effect of this variant was evaluated using intraocular pressure measurements and data on visual field testing / a diagnosis of glaucoma (if available).

**MAIN OUTCOME MEASURES:** The penetrance of the variant rs74315329 was estimated from the percentage of the carriers of the risk

allele of the variant that had high intraocular pressure (ocular hypertension)  
and / or glaucoma.

**RESULTS:** In our study, the observed penetrance of the variant rs74315329  
in relation to raised intraocular pressure was 12.5% and 19.4% in the  
TwinsUK and the Rotterdam Study respectively, suggesting a much lower  
penetrance for high intraocular pressure (and hence, glaucoma) in  
comparison to that reported previously.

**CONCLUSIONS:** The significance of this finding is that higher numbers of  
healthy individuals in the population are expected to be carriers of this  
mutation, which in turn reduces the utility of identifying carriers of this  
mutation as a screening tool for glaucoma.

## Introduction

Glaucoma is the leading cause of irreversible blindness in the world<sup>1</sup>.

Primary open-angle glaucoma (POAG) is the commonest subtype of glaucoma occurring in Caucasian populations, accounting for about 50% of all the glaucoma cases.

Several studies have reported positive family history as a risk factor for glaucoma<sup>2-4</sup>, thus suggesting a role of genetic factors in the development of glaucoma.

Previously, linkage studies have implicated several genetic loci in the Mendelian forms of glaucoma that segregated in families ([www.omim.org](http://www.omim.org)), with the causal gene identified at three of these loci – myocilin (*MYOC*) at the GLC1A locus<sup>5</sup>, optineurin (*OPTN*) at the GLC1E locus<sup>6</sup> and *TBK1* at the GLC1P locus<sup>7</sup>. More recently, the advent of genome-wide association studies (GWAS) has led to the identification of many genetic loci in association with POAG<sup>8-10</sup> and its intermediate phenotypes<sup>11-15</sup>.

*MYOC*, the causal gene at the GLC1A locus (OMIM 601652), was identified in pedigrees with juvenile open-angle glaucoma (JOAG), a term used to refer to POAG with an earlier age of onset and an autosomal dominant mode of inheritance<sup>16</sup>. Sheffield et al. (1993)<sup>17</sup> first reported the GLC1A linkage locus (mapping to chromosome 1q21-q31) in a family with 22 members

129 affected with JOAG. Subsequently, Stone et al. (1997)<sup>5</sup>, using a combination  
130 of fine-mapping and candidate gene approach at the 1q21-q31 locus,  
131 identified missense mutations within the *MYOC* gene [also known as  
132 trabecular meshwork-induced glucocorticoid response protein (*TIGR*) gene]  
133 that segregated with the disease. Since then, several other investigators have  
134 reported *MYOC* mutations segregating within families of JOAG as well as  
135 adult-onset POAG<sup>18–21</sup>. Moreover, analysis of *MYOC* mutations in sporadic  
136 cases of POAG from various ancestries (Caucasian, Asian and African-  
137 American) has demonstrated that a range of probable disease-causing *MYOC*  
138 mutations account for ~2–4% cases<sup>22,23</sup>.

139 To date over 100 *MYOC* gene mutations (~85% of which are missense) have  
140 been reported in association with JOAG and POAG  
141 (<http://www.myocilin.com/variants.php>, last accessed 25 March 2016). Of  
142 these, Gln368Stop (dbSNP accession number: rs74315329) is the  
143 commonest glaucoma-causing *MYOC* mutation (accounting for >40% of the  
144 POAG cases due to *MYOC* mutations) in the population<sup>5,22,23</sup>. The higher  
145 frequency of Gln368Stop among all the known *MYOC* mutations, coupled  
146 with the fact that it has been reported in majority of the populations  
147 investigated so far, suggested that there might be a possible founder effect  
148 for this mutation<sup>23</sup>. Subsequently, studies have demonstrated that the same



disease haplotype for the Gln368Stop mutation was present in 15 unrelated affected Caucasian families settled in Australia<sup>24</sup> and a large affected French-Canadian family<sup>25</sup>, supporting a common ancestral origin for this mutation.

So far, the studies that have evaluated the Gln368Stop *MYOC* mutation in sporadic POAG cases, have demonstrated a high odds of developing the disease with this mutation – Fingert et al. (1999)<sup>23</sup> found that 27/1,693 POAG cases carried the mutation compared to 1/793 controls (OR = 12.84). More recently, Gharahkhani et al. (2015)<sup>26</sup> used an imputation-based method with the 1000 Genomes reference panel in advanced POAG cases from the ANZRAG study, and further affirmed the high effect of the Gln368Stop mutation (OR = 15.53).

The Gln368Stop *MYOC* mutation appears to increase POAG risk by raising the intraocular pressure (IOP): sporadic as well as familial POAG cases harbouring the Gln368Stop mutation have a higher mean IOP compared to the general population, with the mean IOP for the mutation carriers ranging between 27.7 and 30 mm Hg<sup>20,22,27–29</sup>.

The recent availability of large-scale population-based sequencing data has made it possible to evaluate the effect of Gln368Stop on POAG risk in the population at large. Here we aim to test the effect of Gln368Stop (hereafter

also referred to as rs74315329) on IOP, and by extension on POAG, in European population panels using directly sequenced and imputation-based data.

## Materials and Methods

The primary study was conducted in the TwinsUK cohort, a population-based study of healthy twin volunteers<sup>30</sup>. Volunteering twin siblings were unaware of the eye studies interests at the time of enrolment and gave fully informed consent under a protocol reviewed by the St. Thomas' Hospital Local Research Ethics Committee.

As a part of the UK10K project<sup>31</sup>, 1,854 unrelated subjects from the TwinsUK had their whole genome sequenced at a low coverage (average depth of coverage was 6x) at the Wellcome Trust Sanger Institute's core sequencing facility with Illumina's GAII sequencing machines. In addition, another subset of 1,190 TwinsUK subjects (which included some twin pairs) was sequenced at a much higher average depth of coverage (30x-40x). Discrete genotype calls were available for all the variable sites that were identified in the sequencing dataset, which was used to identify the TwinsUK subjects that were carriers of the allele A (hereafter referred to as the 'risk allele') for the variant rs74315329 in the *MYOC* gene.

An additional subset of 3,048 TwinsUK subjects (which included some twin pairs), that was not sequenced but for which Chip genotype data were available (genotyped using two different Illumina genotyping platforms:

209 317K Duo and HumanHap610K-Quad arrays), imputed genotypes based on  
210 the 1000 Genomes Phase 3 reference panel  
211 ([http://csg.sph.umich.edu//abecasis/MACH/download/1000G.Phase3.v5.htm](http://csg.sph.umich.edu//abecasis/MACH/download/1000G.Phase3.v5.html)  
212 [l](#)) were used to identify additional carriers of the risk allele for rs74315329.  
213 Phasing of the genotypes was done using the software MaCH  
214 (<http://csg.sph.umich.edu//abecasis/MACH/tour/imputation.html>) and  
215 genotype imputation for markers in the 1000 Genomes reference panel was  
216 done using the software Minimac  
217 (<http://genome.sph.umich.edu/wiki/Minimac>). Imputed data contains the  
218 probabilities of the possible genotypes at each marker. An arbitrary  
219 threshold of 80% for the probability of a heterozygous genotype was used to  
220 identify carriers of the risk allele for rs74315329.

221 In the TwinsUK cohort, IOP was measured using the Ocular Response  
222 Analyser (ORA), a non-contact air-puff tonometer. The mean IOP of the two  
223 eyes was used for the analysis. Throughout this study, an IOP reading  
224 greater than 21 mm Hg will be considered as ‘high IOP’ i.e. ocular  
225 hypertension. For the individuals that were identified as carriers of the risk  
226 allele for rs74315329, the most recent IOP readings, visual field testing  
227 information and POAG status were obtained through follow-up with their  
228 local optician (which was on an average five years after their initial

recruitment). In all the cases, follow-up IOP at the local optician was measured using a non-contact tonometer. These individuals were also enquired regarding any history of taking IOP-lowering medication and POAG diagnosis / surgery.

For the TwinsUK individuals that were carriers of the risk allele for rs74315329 (identified using the whole-genome sequencing and the 1000 Genomes imputation datasets, as described above), validation of the genotype for this variant was performed using Sanger sequencing. Further details of the Sanger sequencing methodology that was used are provided in the *Supplementary Information* (available at [www.aaojournal.org](http://www.aaojournal.org)).

The Rotterdam Study, a population-based study based in Rotterdam (Netherlands) was used for the replication of the findings observed in the TwinsUK. The Rotterdam study comprises of three cohorts – RSI, RSII and RSIII (combined N = 11,189). In the Rotterdam Study cohorts, imputation data was used to identify the carriers of the risk allele for rs74315329. Genotyping in these cohorts was performed using a combination of genotyping platforms - Illumina Infinium II HumanHap550 array (RS-I), the Illumina Infinium HumanHap 550-Duo array (RS-I, RS-II), and the Illumina Infinium Human 610-Quad array (RS-I, RS-III). Imputation was performed on the Michigan Imputation Server

(<https://imputationserver.sph.umich.edu/index.html>) using the reference panel released by the Haplotype Reference Consortium (HRC) (<http://www.haplotype-reference-consortium.org/>). An arbitrary threshold of 80% for the probability of a heterozygous genotype for rs74315329 was used to identify the risk allele carriers. Exome sequencing data that was available in a subset of the RS-I subjects<sup>32</sup> was used to confirm the genotype for rs74315329 for the individuals that were identified as carriers of the risk allele for this variant using the imputation data. For all three Rotterdam cohorts, IOP from the most recent assessment, measured using Goldmann applanation tonometry, was used. The subjects in all three Rotterdam cohorts also had their optic discs and visual fields assessed in order to detect the presence of glaucomatous optic neuropathy or glaucomatous visual field loss (GVFL)<sup>33</sup>. In addition, any history of taking IOP-lowering medication and POAG diagnosis / surgery was also available. Further details on the Rotterdam Study are available in Hofman et al. (2016)<sup>34</sup>.

## Results

In the TwinsUK, the average read depth for rs74315329 was ~7.5x and ~33x in the low-coverage and the high-coverage sequencing subsets, respectively. Seven individuals (out of a total 3,044) from the sequencing dataset were identified as heterozygous (carriers) for the risk allele (allele A) of the variant rs74315329. No individual was homozygous for the risk allele of this variant.

In the 1000 Genomes–based imputation dataset for the TwinsUK, the variant rs74315329 was well imputed, with an imputation quality score (r-squared) of 0.56. The imputation dataset identified an additional two TwinsUK individuals with greater than 80% probability of a heterozygous genotype for rs74315329. In the imputation dataset, a high probability (>90%) of a heterozygous state for rs74315329 was observed in six of the seven TwinsUK individuals that were initially identified as carriers of the risk allele for this variant in the sequencing dataset (**Table 1**).

Consequently, a total of nine unrelated individuals in the TwinsUK (out of a combined panel of 6,092 individuals) were identified as carriers of the risk allele for rs74315329, using a combination of whole genome sequencing and imputation-based data (**Table 1**). Seven of the nine risk allele carriers did not have data on their co-twin (in their respective datasets). In the case of the

289 remaining two risk allele carriers that had data available on their co-twin  
290 (both were dizygotic twin pairs), the co-twin was not a carrier of the risk  
291 allele i.e. they were homozygous for the non-risk allele of rs74315329.

292 Sanger sequencing confirmed the heterozygous genotype in eight of the nine  
293 carriers of the risk allele for rs74315329 in the TwinsUK (*Supplementary*  
294 *Figure 1*, available at [www.aaojournal.org](http://www.aaojournal.org)). The one risk allele carrier that  
295 failed to validate on Sanger sequencing exhibited a homozygous genotype  
296 for the non-risk allele (allele G) of rs74315329. This individual had been  
297 identified as a risk allele carrier in the sequencing dataset, and the  
298 imputation data suggested that this individual had greater than 99%  
299 probability for a heterozygous state for rs74315329 (**Table 1**). Since this  
300 individual belonged to the sequencing dataset, in which only one co-twin per  
301 pair was sequenced, data on the co-twin of this individual was not available.

302 The minor allele frequency (MAF) of rs74315329 in the combined  
303 TwinsUK panel was ~0.07% (for either scenario – eight or nine risk allele  
304 carriers), which is similar to that observed in the 1000 Genomes project  
305 (0.06%). The exome sequencing databases such as EVS  
306 (<http://evs.gs.washington.edu/EVS/>) and ExAC  
307 (<http://exac.broadinstitute.org/>) report a comparatively higher MAF for  
308 rs74315329 (0.14% and 0.15%, respectively). Exome sequencing projects



typically sequence at a much higher depth of coverage as compared to whole-genome sequencing projects (such as the 1000 Genomes project) – accordingly, a possible under-calling of heterozygous genotypes in the latter could explain the comparatively lower MAF (but in compliance with the 1000 Genomes project) for rs74315329 observed in the TwinsUK.

**Table 1** provides the list of the TwinsUK samples that were identified as carriers of the risk allele for rs74315329 and their findings in the different datasets that were used.

IOP information (either on initial recruitment or on follow-up) was available for eight of the nine TwinsUK individuals that were carriers of the risk allele for rs74315329. Only one of these eight mutation carriers recorded a high IOP (>21 mm Hg), either on initial measurement or on follow-up (**Table 2**).

The mutation carrier with high IOP (Sample No. 7), on follow-up, had also developed visual field defects and had undergone trabeculectomy in both the eyes. For this individual, the IOP prior to trabeculectomy was available only for the left eye (27.3 mm Hg), while the same for the right eye was not available. Post-trabeculectomy, the most recent IOP of this individual had reduced to 12.3 mm Hg (13.3 mm Hg and 11.3 mm Hg, for the right and left eye, respectively).

328 None of the remaining seven mutation carriers recorded a higher than  
329 normal IOP, either on initial measurement or on follow-up (a mean of five  
330 years later). In addition, none of these seven individuals had any history of  
331 taking IOP-lowering medication; and for five of these seven individuals,  
332 visual field data available from the most recent assessment at their local  
333 optician showed no GVFL.

334 In the Rotterdam cohorts, HRC-based imputation data was used to identify  
335 individuals with a heterozygous genotype (carriers) for rs74315329. Twelve,  
336 seven and twelve individuals were identified as carriers of the risk allele for  
337 rs74315329 in the RS-I, RS-II and RS-III, respectively. The heterozygous  
338 genotype for rs74315329 was confirmed in all six carriers (out of twelve) in  
339 the RS-I that also had exome sequencing data. In the RS-I, three of the  
340 twelve carriers of the risk allele for rs74315329 who had normal IOP on  
341 assessment were on IOP-lowering medication; it is therefore assumed that  
342 these three individuals had ocular hypertension before the initiation of  
343 treatment. None of the 12 mutation carriers showed any GVFL. In the RS-II,  
344 two of the seven mutation carriers were previously diagnosed with glaucoma  
345 (with high IOP) and have had laser surgery for the same (only one of these  
346 two individuals showed GVFL on assessment). Another RS-II mutation  
347 carrier, who initially had normal IOP on IOP-lowering medication, provided

history of glaucoma laser surgery on follow-up visit. In the RS-III, none of the 12 mutation carriers had high IOP, were on IOP-lowering medication, showed GVFL on assessment, or reported any history of glaucoma. Details such as the heterozygous genotype probability, IOP and age of the mutation carriers in the RS-I, RS-II and RS-III are summarised in *Supplementary Table 1* (available at [www.aaojournal.org](http://www.aaojournal.org)).

Overall, in the TwinsUK, one of the eight carriers of the risk allele for the *MYOC* variant rs74315329 had high IOP; while in the Rotterdam Study (RS I-III), 6 of the 31 risk allele carriers had high IOP, and three of those six individuals have been diagnosed with POAG. For rs74315329, this corresponds to a penetrance of 12.5% (95% C.I. = 0.7% - 53.3%) and 19.4% (95% C.I. = 8.1% - 38.1%) with respect to high IOP or ocular hypertension, in the TwinsUK and the Rotterdam Study, respectively. Likewise, the penetrance of rs74315329 with respect to POAG is 9.7% (95% C.I. = 2.5% - 26.9%) in the Rotterdam Study, in which a complete assessment for POAG was available. An age-dependent penetrance (with respect to high IOP and POAG) of the variant rs74315329 in the TwinsUK and the Rotterdam Study is summarised in **Table 3**.

Only one other *MYOC* variant (rs202176570), of the remaining 17 variants that have been catalogued in the OMIM database

(<http://www.omim.org/entry/601652>), was non-monomorphic in the  
TwinsUK sequencing dataset. This variant, however, was too rare (just one  
heterozygous individual) to enable any meaningful assessment of its effect  
on IOP.

## Discussion

In this study, we analysed the effect of the known glaucoma-causing *MYOC* mutation Gln368Stop (variant rs74315329) using whole genome sequence data and imputed data based on large scale population-based sequencing panels. POAG cases with this variant often have very high IOPs, on average 30 mm Hg<sup>35</sup>. The protein product of the *MYOC* gene, which has a cytoskeletal function, is widely expressed in ocular tissues, in particular the trabecular meshwork<sup>18,36</sup>. *MYOC* mutations (including the Gln368Stop mutation) lead to a buildup of abnormal protein in the trabecular meshwork, which impairs the trabecular outflow of aqueous humour, thus raising the IOP<sup>37</sup>. This suggests that the *MYOC* mutations possibly exert a toxic gain-of-function effect, a finding that has been verified by *MYOC*-knockout studies in mice<sup>38</sup>. For some of the subjects in our study, comprehensive glaucoma assessment (optic disc imaging and visual field testing) was unavailable or was obtained via their local optician. Given that the disease-causing *MYOC* mutations (including rs74315329) cause POAG by raising the IOP, the complete availability of IOP measurements in the risk allele carriers for rs74315329 allowed us to evaluate its penetrance with relation to POAG, using IOP as a proxy. In our study, seven of the eight risk allele carriers for rs74315329 in the TwinsUK, and 25 of the 31 risk allele carriers

for rs74315329 in the Rotterdam Study, had IOP less than or equal to 21 mm Hg.

So far, majority of the studies that have evaluated the association of the *MYOC* variant rs74315329 (the Gln368Stop mutation) with ocular hypertension and / or POAG have implicated a much higher penetrance compared to what was observed in our study<sup>22,27,28,35</sup>. For instance, Allingham et al. (1998)<sup>27</sup> observed that the penetrance of the Gln368Stop mutation was 100% and 78% with respect to ocular hypertension and POAG respectively by age 70; similarly, for the same mutation, Fingert et al. (2002)<sup>35</sup> reported a penetrance with respect to POAG as high as 90%. In our study, the observed penetrance of the *MYOC* variant rs74315329 for ocular hypertension was 12.5% and 19.4% in the TwinsUK and the Rotterdam Study, respectively. Part of the reason for the reduced penetrance of rs74315329 observed in our study is that previous studies might have overestimated its penetrance, they being either family-based studies or population-based case-control studies. Mutations can show increased penetrance in family-based studies due to more ready ascertainment of families with multiple affected individuals as well as due to the existence of additional genetic or environmental modifiers within families<sup>39</sup>. On the other hand, population-based case-control studies, by design, tend to oversample

for cases, which can overestimate the penetrance of mutations if the population prevalence of the disease is not accounted for<sup>40</sup>.

Accounting for the known population prevalence of POAG, we estimated the expected penetrance of rs74315329, based on the previously reported odds ratios (12.8 to 15.5) for the risk allele of rs74315329<sup>23,26</sup>. Given a population prevalence rate for POAG in Caucasians aged between 40 and 80 years (age group of the risk allele carriers for rs74315329 observed in the TwinsUK and the Rotterdam Study) of ~2.5%<sup>41</sup>, the expected POAG prevalence rate among the risk allele carriers for rs74315329 (i.e. the expected penetrance of rs74315329) can be estimated to range between 24.2% and 27.9% (the calculation has been approximated based on the fact that the population prevalence of POAG and the MAF of rs74315329 are both small). The observed penetrance of rs74315329 for ocular hypertension in the TwinsUK and the Rotterdam Study (12.5% and 19.4% respectively) may be even lower for POAG, since not all individuals with ocular hypertension progress to POAG<sup>42</sup>. In fact, POAG assessment in the Rotterdam Study has shown that thus far only three of the six mutation carriers with high IOP show any evidence of GVFL. As is evident, even after accounting for the known population prevalence of POAG, the penetrance of rs74315329 for ocular hypertension, and by extension for

POAG, observed in our study, is lower than what would be expected based on the odds ratio estimates reported by previous studies.

Since the penetrance of the variant rs74315329 in relation to POAG is known to increase with age<sup>27,28</sup>, a finding that was also corroborated by our study (**Table 3**), the age of our cohorts in comparison to the previous studies is an important consideration. Alward et al. (1998)<sup>22</sup>, one of the studies that we used for the estimation of the expected penetrance of rs74315329 (as described above), reported that the average age of POAG diagnosis among the Gln368Stop mutation carriers in their study was 59 years. In our study, the mean age of the 32 mutation carriers that did not have raised IOP or a diagnosis of POAG was 65.2 years. In the case of our youngest cohort (RS-III), though all the twelve mutation carriers (without raised IOP or a diagnosis of POAG), barring one, were older than 50 years, only three of them were older than 59 years. For the remaining three cohorts (TwinsUK, RS-I and RS-II), 19 of the 20 mutation carriers without raised IOP or a diagnosis of POAG were older than 59 years. Thus, barring the RS-III to an extent, we do not expect the age of our cohorts to significantly impact the estimation of the penetrance of the *MYOC* variant.

To date, in the studies that evaluated the penetrance of mutations, the number of control subjects that were analysed was limited in number. The



recent availability of large-scale population-based sequencing panels has made it possible to ascertain the penetrance of a number of known disease-causing mutations using sufficiently powered population-based studies. We believe that our estimation of the penetrance of the Gln368Stop *MYOC* mutation i.e. rs74315329 using a population-based panel of over 17,000 subjects might represent a more “realistic” measure of its penetrance compared to its previous estimates.

This observation of a lower than expected penetrance of the *MYOC* variant rs74315329 is in accordance with recent findings for mutations that have previously been implicated in diseases<sup>31,43,44</sup>. Narasimhan et al. (2016)<sup>44</sup> sequenced the exomes of ~3,000 Pakistanis with high levels of consanguinity and observed that there were as many as 29 instances of rare homozygous loss-of-function mutations in genes catalogued in the OMIM database in individuals that showed no manifestations consistent with the expected OMIM phenotype.

The implication of the reduced penetrance of the Gln368Stop *MYOC* mutation (which results in premature termination of the myocilin protein) is that higher numbers of healthy individuals in the population are expected to be carriers of this mutation than estimated previously. Hence, the finding of this mutation in an individual would require cautious interpretation. The

reduced penetrance also implies that the genotype-phenotype correlation between this mutation and POAG is likely to be much weaker than estimated previously, thus potentially reducing the utility of knowing the genotype at rs74315329 as a predictive tool in identifying those at a high-risk of developing POAG. Nonetheless, given the difficulties and poor efficacy of screening for glaucoma with current paradigms<sup>45</sup>, using genetic variants that offer even modest predictive value might still be useful to target subjects for screening.

A limitation of the TwinsUK cohort is that it is a volunteer-based cohort with a potential “healthy volunteer” bias. If such a bias were true, then twins suffering from sight-impairing severe glaucoma might be less likely to volunteer. However, the prevalence of common diseases and lifestyle characteristics in the TwinsUK is comparable to that of age-matched population-based studies<sup>46</sup>. Moreover, the estimated prevalence of the variant rs74315329 in the TwinsUK is similar to the expected population prevalence. Another potential limitation of our study is that in the Rotterdam cohorts the variant rs74315329 was imputed, and it was possible to confirm the imputation calls in only a subset of them that were also sequenced. But given that Sanger sequencing validated the imputation calls for this variant in the TwinsUK, and that previous studies have confirmed the validity of

imputation for this variant<sup>26</sup>, this is unlikely to have a significant impact on our results.

In conclusion, we reported the findings of the largest study to date evaluating the penetrance of the most common genetic mutation causing POAG. Given the rarity of this mutation and its much lower penetrance (than known previously) for ocular hypertension (and hence, POAG), our study suggests that screening for this mutation would not be useful on its own. But known carriers of this mutation would require careful monitoring, although they might be reassured that it is not always disease-causing.

## **Acknowledgements**

We gratefully thank the invaluable contributions of all the staff that have helped in the recruitment, in particular Diana Kozareva.

## References

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* 2006;90:262–267.
2. Sommer A. Glaucoma risk factors observed in the Baltimore Eye Survey. *Curr Opin Ophthalmol* 1996;7:93–98.
3. Wolfs RC, Klaver CC, Ramrattan RS, et al. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. *Arch Ophthalmol* 1998;116:1640–1645.
4. Leske MC, Wu SY, Hennis A, et al. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. *Ophthalmology* 2008;115:85–93.
5. Stone EM, Fingert JH, Alward WL, et al. Identification of a gene that causes primary open angle glaucoma. *Science* (80- ) 1997;275:668–670.
6. Rezaie T, Child A, Hitchings R, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. *Science* (80- ) 2002;295:1077–1079.
7. Fingert JH, Robin AL, Stone JL, et al. Copy number variations on chromosome 12q14 in patients with normal tension glaucoma. *Hum Mol Genet* 2011;20:2482–2494.
8. Bailey JNC, Loomis SJ, Kang JH, et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. *Nat Genet* 2016;48:189–194.
9. Burdon KP, Macgregor S, Hewitt AW, et al. Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. *Nat Genet* 2011;43:574–578.
10. Wiggs JL, Yaspan BL, Hauser MA, et al. Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma. *PLoS Genet* 2012;8:e1002654.
11. Ramdas WD, van Koolwijk LM, Ikram MK, et al. A genome-wide association study of optic disc parameters. *PLoS Genet* 2010;6:e1000978.
12. Nag A, Venturini C, Small KS, et al. A genome-wide association study of intraocular pressure suggests a novel association in the gene FAM125B in the TwinsUK cohort. *Hum Mol Genet* 2014;23:3343–3348.
13. van Koolwijk LM, Ramdas WD, Ikram MK, et al. Common genetic determinants of intraocular pressure and primary open-angle glaucoma. *PLoS Genet* 2012;8:e1002611.
14. Hysi PG, Cheng C-Y, Springelkamp H, et al. Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma. *Nat Genet* 2014;46:1126–1130.
15. Springelkamp H, Hohn R, Mishra A, et al. Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process. *Nat Commun* 2014;5:4883.
16. Johnson AT, Drack A V, Kwitek AE, et al. Clinical features and linkage analysis of a family with autosomal dominant juvenile glaucoma. *Ophthalmology* 1993;100:524–529.
17. Sheffield VC, Stone EM, Alward WL, et al. Genetic linkage of familial open angle glaucoma to chromosome 1q21-q31. *Nat Genet* 1993;4:47–50.

18. Adam MF, Belmouden A, Binisti P, et al. Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma. *Hum Mol Genet* 1997;6:2091–2097.
19. Wiggs JL, Allingham RR, Vollrath D, et al. Prevalence of mutations in TIGR/Myocilin in patients with adult and juvenile primary open-angle glaucoma. *Am J Hum Genet* 1998;63:1549–1552.
20. Vincent AL, Billingsley G, Buys Y, et al. Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene. *Am J Hum Genet* 2002;70:448–460.
21. Suzuki Y, Shirato S, Taniguchi F, et al. Mutations in the TIGR gene in familial primary open-angle glaucoma in Japan. *Am J Hum Genet* 1997;61:1202–1204.
22. Alward WL, Fingert JH, Coote MA, et al. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). *N Engl J Med* 1998;338:1022–1027.
23. Fingert JH, Heon E, Liebmann JM, et al. Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. *Hum Mol Genet* 1999;8:899–905.
24. Baird PN, Craig JE, Richardson AJ, et al. Analysis of 15 primary open-angle glaucoma families from Australia identifies a founder effect for the Q368STOP mutation of myocilin. *Hum Genet* 2003;112:110–116.
25. Baird PN, Richardson AJ, Mackey DA, et al. A common disease haplotype for the Q368STOP mutation of the myocilin gene in Australian and Canadian glaucoma families. *Am J Ophthalmol* 2005;140:760–762.
26. Gharahkhani P, Burdon KP, Hewitt AW, et al. Accurate Imputation-Based Screening of Gln368Ter Myocilin Variant in Primary Open-Angle Glaucoma. *Invest Ophthalmol Vis Sci* 2015;56:5087–5093.
27. Allingham RR, Wiggs JL, De La Paz MA, et al. Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma. *Invest Ophthalmol Vis Sci* 1998;39:2288–2295.
28. Craig JE, Baird PN, Healey DL, et al. Evidence for genetic heterogeneity within eight glaucoma families, with the GLC1A Gln368STOP mutation being an important phenotypic modifier. *Ophthalmology* 2001;108:1607–1620.
29. Hewitt AW, Bennett SL, Fingert JH, et al. The optic nerve head in myocilin glaucoma. *Invest Ophthalmol Vis Sci* 2007;48:238–243.
30. Moayyeri A, Hammond CJ, Valdes AM, Spector TD. Cohort Profile: TwinsUK and healthy ageing twin study. *Int J Epidemiol* 2013;42:76–85.
31. Walter K, Min JL, Huang J, et al. The UK10K project identifies rare variants in health and disease. *Nature* 2015;526:82–90.
32. Amin N, Jovanova O, Adams HHH, et al. Exome-sequencing in a large population-based study reveals a rare Asn396Ser variant in the LIPG gene associated with depressive symptoms. *Mol Psychiatry* 2016.
33. Czudowska MA, Ramdas WD, Wolfs RCW, et al. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam Study. *Ophthalmology* 2010;117:1705–1712.
34. Hofman A, Brusselle GGO, Darwish Murad S, et al. The Rotterdam Study: 2016 objectives and design update. *Eur J Epidemiol* 2015;30:661–708.

35. Fingert JH, Stone EM, Sheffield VC, Alward WLM. Myocilin glaucoma. *Surv Ophthalmol* 2002;47:547–561.
36. Tamm ER. Myocilin and glaucoma: facts and ideas. *Prog Retin Eye Res* 2002;21:395–428.
37. Fingert JH. Primary open-angle glaucoma genes. *Eye (Lond)* 2011;25:587–595.
38. Kim BS, Savinova O V, Reedy M V, et al. Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function. *Mol Cell Biol* 2001;21:7707–7713.
39. Latourelle JC, Sun M, Lew MF, et al. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson’s disease: the GenePD study. *BMC Med* 2008;6:32.
40. Gail MH, Pee D, Benichou J, Carroll R. Designing studies to estimate the penetrance of an identified autosomal dominant mutation: cohort, case-control, and genotyped-proband designs. *Genet Epidemiol* 1999;16:15–39.
41. Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* 2014;121:2081–2090.
42. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. *Arch Ophthalmol (Chicago, Ill 1960)* 2002;120:714–730.
43. Johnston JJ, Lewis KL, Ng D, et al. Individualized iterative phenotyping for genome-wide analysis of loss-of-function mutations. *Am J Hum Genet* 2015;96:913–925.
44. Narasimhan VM, Hunt KA, Mason D, et al. Health and population effects of rare gene knockouts in adult humans with related parents. *Science* 2016;352:474–477.
45. Quigley HA. Current and future approaches to glaucoma screening. *J Glaucoma* 1998;7:210–220.
46. Andrew T, Hart DJ, Snieder H, et al. Are twins and singletons comparable? A study of disease-related and lifestyle characteristics in adult women. *Twin Res* 2001;4:464–477.